S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer | NCT00041067 | Trialant

S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer | NCT00041067 | Trialant

Official Title: Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Colony-stimulating factors, such as filgrastim, may help a person's immune system recover from the side effects of chemotherapy.

PURPOSE: Phase II trial to study the effectiveness of combining trastuzumab with docetaxel, vinorelbine, and filgrastim in treating women who have stage IV breast cancer.
Detailed Description: OBJECTIVES:

Determine the 1-year survival of women with HER2-positive stage IV breast cancer treated with trastuzumab (Herceptin), docetaxel, and vinorelbine with filgrastim (G-CSF) support.

Determine the response rate (complete and partial, confirmed and unconfirmed) in the subset of patients with measurable disease treated with this regimen.

Determine the progression-free survival of patients treated with this regimen.

Determine the qualitative and quantitative toxic effects of this regimen in these patients.

Obtain tissue blocks for the determination of predictors of response (e.g., beta-tubulin mutations) to microtubule interacting agents in this patient population and for other future studies.

OUTLINE: This is a pilot, multicenter study.

Patients receive docetaxel IV over 1 hour on day 1, filgrastim (G-CSF) subcutaneously on days 2-21, vinorelbine IV over 6-10 minutes on days 8 and 15, and trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. If docetaxel and vinorelbine are discontinued due to unacceptable toxicity, patients may continue to receive trastuzumab. If trastuzumab is discontinued due to unacceptable toxicity, patients may continue to receive chemotherapy with G-CSF support.

Patients are followed every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study within 18-22.5 months.

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No
Eligibility Criteria: DISEASE CHARACTERISTICS:

Histologically confirmed stage IV breast cancer

Metastasis to the ipsilateral supraclavicular lymph nodes allowed

HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting

No effusions or ascites as only sites of disease

No primary or metastatic brain or central nervous system tumor

Hormone receptor status:

Not specified

PATIENT CHARACTERISTICS:

Age:

18 and over

Sex:

Female

Menopausal status:

Not specified

Performance status:

Zubrod 0-2

Life expectancy:

Not specified

Hematopoietic:

Absolute neutrophil count at least 1,500/mm^3

Platelet count at least 100,000/mm^3

Hepatic:

Bilirubin normal

aspartate aminotransferase or Alanine aminotranferease no greater than 1.5 times upper limit of normal (ULN)

Alkaline phosphatase no greater than 2.5 times ULN

Renal:

Not specified

Cardiovascular:

left ventricular ejection fraction normal by multigated radionuclide angiography or echocardiogram (patients who have received prior anthracycline therapy)

No clinical evidence or history of cardiomyopathy

Other:

No pre-existing grade 2 or greater motor or sensory peripheral neuropathy except abnormalities due to cancer

No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80

No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer currently in complete remission

No known sensitivity to E. coli-derived proteins

Not pregnant or nursing

Negative pregnancy test

Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

At least 6 months since prior chemotherapy

Prior anthracycline as adjuvant therapy allowed

No prior cumulative dose of doxorubicin more than 360 mg/m^2

No prior cumulative dose of epirubicin more than 720 mg/m^2

No more than 1 prior adjuvant or neoadjuvant chemotherapy regimen for primary disease

No prior docetaxel

No prior vinorelbine

Prior paclitaxel allowed

Endocrine therapy:

Prior hormonal therapy as adjuvant therapy or for metastatic breast cancer allowed

No concurrent hormonal therapy

Radiotherapy:

At least 3 weeks since prior radiotherapy

Surgery:

At least 2 weeks since prior surgery and recovered